A new antihypertensive compound: 3 hydrazino-6- [(2-hydroxypropyl)methylamino] pyridazine dihydrochloride (ISF 2123).
D000284:Administration, Oral; D000818:Animals; D000959:Antihypertensive Agents; D001794:Blood Pressure / Q000187:drug effects*; D002415:Cats; D004195:Disease Models, Animal; D004285:Dogs; D006168:Guinea Pigs; D006634:Histamine H1 Antagonists; D006830:Hydralazine / Q000494:pharmacology / Q000627:therapeutic use*; D006834:Hydrazines / Q000494:pharmacology / Q000627:therapeutic use / Q000633:toxicity; D006977:Hypertension, Renal / Q000188:drug therapy*; D066298:In Vitro Techniques; D007275:Injections, Intravenous; D009130:Muscle, Smooth / Q000187:drug effects; D010276:Parasympatholytics; D011724:Pyridazines / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D051381:Rats; D013045:Species Specificity
D000959:Antihypertensive Agents; D006634:Histamine H1 Antagonists; D006834:Hydrazines; D010276:Parasympatholytics; D011724:Pyridazines; D006830:Hydralazine; C009978:propildazine